skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

ジェネリック医薬品、バイオシミラーの情報源として

Generics_Bulletin2

日本国内では2020年9月までにジェネリック医薬品の使用割合を80%にする目標を挙げています。このような中、Generics Bulletinはグローバルな専門アナリスト&ジャーナリストの広範なネットワークを駆使して、世界中の市場動向を追跡することで、貴重なニュースを提供しています。また、市場プレーヤーのトップエグゼクティブやオピニオンリーダーのインタビューなども定期的に掲載しています。

深い専門性と具体的なデータに基づいたニュースレポートは、世界の大手ジェネリック医薬品メーカーの戦略を明らかにし、その計画、ポートフォリオ、業績を分析&報告します。

Generics Bulletinでは以下のトピックをカバーしています。

  • 規制・コンプライアンスの変更
  • 法規制の進展
  • 競合製品の開発
  • 合併・買収活動
  • 新製品の発売
  • マーケティングの課題
  • 広告戦略など

このサービスの特徴

無料の最新記事&レポート

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Multiple Molecules See UK Prices More Than Double In December

    18 Jan 2022

    GB2109_Price_watch_UK_2_2AP631W_1200

    WaveData’s compilation of the fastest-rising UK generics prices in December showed several products across multiple presentations more than doubling their average trade prices to independent pharmacists.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Bio-Thera’s Bevacizumab US Action Date Passes Without Approval

    01 Dec 2021

    GB2112_27_November_2021_Calendar_2GY47JX_1200

    Bio-Thera Solutions had been hoping to become the first Chinese biosimilars developer to win an FDA approval, for its BAT1706 bevacizumab candidate. However, the announced FDA action date for the application has come and gone with no word from the company or regulator.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    ANI Pharmaceuticals Completes $210m Novitium Acquisition

    By Chloe Kent 30 Nov 2021

    GB2111_Handshake_Paper_Cutouts_E7N2BK_1200

    ANI Pharmaceuticals has completed its acquisition of niche generics specialist Novitium Pharma, securing access to a pipeline of generics and 505(b)(2) candidates that has expanded further since the deal was announced earlier in the year.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Teva And Endo Overcome Opioid Claims In California

    02 Nov 2021

    PS2107_opioidsstates_2C4EAH2_1200

    Following a recent settlement in Louisiana, Teva has been told by a court in California it is not liable for the state’s opioid crisis, avoiding for now the potential for significant damages.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    India Biosimilars Landscape

    12 Oct 2021

    India Biosimilars Landscape

    India leads the ways with the highest number of approved biosimilars.

    Topic clinical-trials biosimilars

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    EU’s Health Emergency Response Plans Must Address Existing Flaws

    17 Sep 2021

    GB2109_EU_Flag_COVID_Coronavirus_2BD8JRX_1200

    The EU’s creation of a Health Emergency Response Authority to deal with future health threats has been welcomed by off-patent industry association Medicines for Europe. However, the organization pointed out current policy and regulatory weaknesses that must be addressed if HERA is to be successful.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    MPP Celebrates First UMIC Dolutegravir Shipments

    14 Sep 2021

    GB2109_Azerbaijan_Belarus_flags_2DMGYB5_1200

    The Medicines Patent Pool has announced that the first shipments of dolutegravir under a fresh agreement covering upper-middle-income countries have reached Azerbaijan and Belarus.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Alkem Delivers Strong Quarter With Domestic Recovery

    By Akriti Seth 14 Sep 2021

    GB2109_Graphs_Up_Arrows_Blue_Yellow_Green_TAWEXE_1200

    India’s Alkem has delivered a strong quarter with a boost in its domestic business on the back of “strong volume-led growth in the acute therapies and faster than market growth in chronic therapies.” However, the company saw a slight YoY decline in the US.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Dr Reddy’s Gears For Sputnik Light In India, Jab For Adolescents

    30 Jul 2021

    SputnikV_ArgentinaGetty_1250_

    Dr Reddy’s is to press ahead with India filing plans for single-dose COVID-19 vaccine Sputnik Light and also expects to “build on” the Russian partner’s trial in adolescents of the two-dose Sputnik V. The company also pilots a partnered first-of-its-kind cashless digital health offering.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Indian Leaders Begin Unique Collaboration On Molnupiravir

    By Akriti Seth 01 Jul 2021

    GB2106_India_COVID_2E96KD7_1200

    Major Indian pharmaceutical companies including Cipla, Dr Reddy’s, Emcure, Sun and Torrent have entered into a first-of-its-kind collaboration to jointly sponsor, supervise and monitor the clinical trial of the investigational oral anti-viral drug molnupiravir to fight against COVID-19 in India. 

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Aspen Faces Vaccine Setback In South Africa As Strides Explores Oral COVID Treatment

    By Akriti Seth 22 Jun 2021

    GB2106_COVID_2CAG8G3_1200

    After a production setback, Aspen and Johnson & Johnson announce a donation of 300,000 vaccines to South African teachers. Strides partners with Ennaid for an oral COVID drug, while Dr Reddy’s, Lupin, Cipla and Sun Pharma Partner with Eli Lilly for baricitinib in India and Formycon receives approval for early action for its COVID-19 drug.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

    By Akriti Seth 16 Jun 2021

    GB2106_Biden_Harris_2CD06C5_1200

    After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    New COVID-19 Vaccine Patent Database Launched

    11 Jun 2021

    PS2106_Database_E0GPRM_1200

    As part of its drive to maximize global access to coronavirus vaccines, the Medicines Patent Pool has developed a publicly accessible resource giving information on the patent status of approved and candidate vaccines.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Celltrion Opens Up Canadian Market For Remsima SC

    By David Wallace 08 Jun 2021

    GB2106_Canada_Open_Door_Flag_DYRCJR_1200

    Celltrion has pushed into another new market with its Remsima SC subcutaneous version of infliximab, launching the innovative biosimilar in Canada.

  • Generics Bulletin: ジェネリック&バイオシミラーニュース

    Industry Steps Up To Help India Through Second Wave

    By Akriti Seth 28 Apr 2021

    GB2104_India_flag_covid_2CF9PDG_1200

    As India sees a consistent rise in daily cases and deaths due to COVID-19, the off-patent industry is stepping up to make drugs affordable and available. Zydus Cadila is seeking approval for virafin, while Natco has applied for molnupiravir approval. Vaccine production and availability has also come under focus. 

医薬品産業専門のジャーナリスト&アナリスト

Editor

Aidan Fry

Editor, Executive Editor, Commercial/R&D

UK

Aidan Fry

Aidan specializes in

  • Biosimilars
  • Generics
  • Legal Issues And Intellectual Property
  • Market intelligence

22+ years of experience

無料トライアル&お問い合わせ

ニュースサービスでは無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

新型コロナウイルス感染拡大防止のため在宅勤務を実施しています。お問い合わせの際は下記のフォームまたはメールアドレスをご利用下さい。

Eメール:inquiry.jp@informa.com


オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。